Immunovant Quarterly Income Statement
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
30.47+0.21 (+0.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunovant revenue and earnings
Immunovant reported a net loss of $153.2 million, compared with a loss of $120.6 million a year earlier. Diluted earnings per share came in at -$0.75.
Summary generated from market data by MetaCap's automated system. Methodology
Immunovant income statement (quarterly)
| Quarter (USD) | Q1 20272026-06-30 | Q4 20262026-03-31 | Q3 20262025-12-31 | Q2 20262025-09-30 | Q1 20262025-06-30 | Q4 20252025-03-31 | Q3 20252024-12-31 | Q2 20252024-09-30 | Q1 20252024-06-30 | Q4 20242024-03-31 | Q3 20242023-12-31 | Q2 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 160.32M | 159.55M | 114.36M | 131.76M | 127.22M | 113.83M | 114.30M | 115.74M | 94.28M | 80.88M | 61.55M | 61.80M |
| Research & Development | 142.63M | 142.29M | 98.92M | 114.25M | 101.20M | 93.65M | 94.52M | 97.27M | 75.47M | 66.06M | 48.34M | 47.96M |
| Other Income (Expense) | 4.00K | 798.00K | -54.00K | 250.00K | 1.19M | 1.07M | -1.26M | 629.00K | 28.00K | -2.59M | 1.09M | 20.00K |
| Pretax Income | -153.22M | -150.70M | -109.08M | -125.91M | -119.70M | -105.87M | -110.97M | -109.04M | -87.07M | -75.09M | -51.53M | -58.21M |
| Income Tax | 0 | -2.84M | 1.55M | 594.00K | 913.00K | 583.00K | 152.00K | 78.00K | 77.00K | 232.00K | -108.00K | 454.00K |
| Net Income | -153.22M | -147.86M | -110.64M | -126.50M | -120.61M | -106.45M | -111.12M | -109.12M | -87.15M | -75.32M | -51.42M | -58.66M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.75 | -0.72 | -0.61 | -0.73 | -0.71 | -0.63 | -0.76 | -0.74 | -0.60 | -0.50 | -0.36 | -0.45 |
| EPS (Diluted) | -0.75 | -0.72 | -0.61 | -0.73 | -0.71 | -0.63 | -0.76 | -0.74 | -0.60 | -0.50 | -0.36 | -0.45 |
| Shares Outstanding (Basic) | 205.55M | — | 181.51M | 173.64M | 170.87M | — | 146.92M | 146.47M | 146.09M | — | 144.52M | 131.16M |
| Shares Outstanding (Diluted) | 205.55M | — | 181.51M | 173.64M | 170.87M | — | 146.92M | 146.47M | 146.09M | — | 144.52M | 131.16M |
This table shows 12 quarterly periods of Immunovant's income statement, from Q1 2027 back to Q2 2024, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow IMVT's reporting calendar. What is a income statement?